The suspension of visas in a large part of the autonomous communities in the context of a pandemic such as the current one has brought to the fore the historical requests of patients with EPOC The anticoagulated.
Not surprisingly, triple therapy for COPD or DOACs are some of the medications that have to overcome this administrative procedure in normal circumstances.
To their demands are also added those of the Spanish Diabetes Federation, which has recently presented a manifesto backed by seven scientific societies in which it claims the urgent review of visas of drugs indicated for this disease.
As they underline, the temporary elimination of visas in many autonomous communities has served to show that their elimination does not imply any risk for patients.
The petition is supported by the three primary care scientific societies (Semfyc, Semergen y Semg) and also has the support of the Spanish Diabetes Society, the Spanish Society of Cardiology, the Spanish Society of Endocrinology and Nutrition and the Spanish Society of Internal Medicine.
Patients insist that this regulatory framework, in force since 2007, represents a limitation in access to medicines in diseases such as diabetes. They emphasize that today, the measure “It lacks foundation and responds, on some occasions, to a control of spending”.
Therefore, they request the competent authorities the revision of the criteria governing the establishment of visas for antidiabetic drugs, so that in the future comply with scientific evidence and the recommendations of national clinical guidelines and international.
In the case of diabetes, the consequences of obstacles in accessing these treatments are clear, from the perspective of the federation. They emphasize that on the one hand, contributes to less well controlled diabetes and leads to multiple complications and, on the other, increase health spending, both directly and indirectly.
The arguments of clinicians
For their part, the specialists from the scientific societies that sign the manifesto point out that in many cases, the affected people do not get the visa acceptance, motivated because, despite having the proper medical prescription, economic criteria are put before clinical ones with their consequences in health outcomes.
They also insist that if the objective of the visa were to control the adequacy of the prescription to the indication, they emphasize that, today, electronic prescription systems already allow the establishment of control mechanisms and audits sufficient to reduce or eliminate the need for this procedure.